Clinical Trial

Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application

Recruiting
View on ClinicalTrials.gov →
Summary
Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-12.
Trial Details
NCT Number NCT06883214
Lead Sponsor Regina Elena Cancer Institute
Collaborators: University of Roma La Sapienza, San Camillo Hospital, Rome, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Neuromed IRCCS
Conditions Glioma
Enrollment 10 participants
Start Date 2023-01-17
Primary Completion 2027-01-17 (estimated)
Study Completion 2027-01-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-05